Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Halozyme owns an enzyme that lets a drug be injected under the skin instead of infused, and takes royalties for it.
Large biologic drugs have to be infused intravenously over hours in a clinic. The company's enzyme temporarily loosens subcutaneous tissue, and the same drug is given as an injection in minutes. For the patient that is the difference between a hospital trip and an injection at home; for the manufacturer it is a way to extend a brand's life.
The company sells nothing itself: it licenses the technology to pharmaceutical giants and takes a share of their sales. Costs are minimal, so profitability is exceptionally high. Risks: expiry of the patents on the technology itself, dependence on a few partner drugs and litigation. The company pays no dividend but buys back stock actively.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Halozyme Therapeutics, Inc. (HALO) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Halozyme Therapeutics, Inc. (HALO) on October 30, 2026 is 130.92 $, −0.20 % on the day. Over the past year the price changed by +75.27 %. The P/E ratio is 36.10, which is above the sector median (24.61). Market capitalization is 14.93 billion $, rank 7 among 132 stocks of the same industry with a known capitalization.
Halozyme Therapeutics, Inc. trades on Nasdaq under the ticker HALO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks HALO has traded between 61.23 $ and 119.21 $. As of 30 October 2026 the price stood 95.88 % of the way from the 52-week low to the high.
Over one year HALO shares rose 75.27 %; over six months they rose 71.67 %. Volatility over 90 days is 41.54 %. Dividends are not included: this is price change only, as of 30 October 2026.
HALO trades at a price-to-earnings ratio of 36.1, above the sector median of 24.6. Price to sales is 9.0, above the sector median of 3.6. Price to book is 104, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Halozyme Therapeutics, Inc. reported revenue of 1.7B $ and net income of 414M $ over the last four quarters. Net margin is 24.86 %. Revenue changed by +41.15 % year over year. Earnings per share are 3.41 $. Market capitalisation is 14.9B $.
HALO has a return on equity of 288.13 %, above the sector median of −40.58 %. Return on assets is 16.05 %, above the sector median of −30.08 %. Operating margin is 35.90 %, above the sector median of −20.96 %.